Total Utang marang Modal Mainz Biomed (MYNZ)

Mainz Biomed N.V. - logo grafis emiten MYNZ

Mainz Biomed N.V. (MYNZ) generates revenue by providing a non-invasive alternative to colonoscopies for patients and clinics. The company relies on partnerships with global laboratories, delegating the processing of genetic data through standardized systems. Revenues are based on the commercialization of stool DNA analysis (ColoAlert) for the detection of intestinal tumors. The price action reflects that the total debt-to-equity ratio is 1.24.

mainzbiomed.com (MYNZ): Rasio Utang marang Ekuitas saka 04.07.2022 nganti 11.03.2026

Rincian metrik lan analitis perusahaan mainzbiomed.com (MYNZ)

- rega saham lan konsensus proyeksi valuasi:
Rega saham Mainz Biomed N.V.|MYNZ - Target konsensus
- rincian kapitalisasi pasar:
Kapitalisasi pasar Mainz Biomed|MYNZ - Nilai Perusahaan
- indikator kapitalisasi buku:
Aset Bersih saben Siji Saham Mainz Biomed|MYNZ - Kapitalisasi Akuntansi|Rasio Kapitalisasi Pasar marang Nilai Buku mainzbiomed.com|MYNZ - Gunggung Aset Perusahaan
- rincian utang lan likuiditas:
Total Utang marang Modal Mainz Biomed N.V.|MYNZ - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Mainz Biomed|MYNZ - Kewajiban utang agregat|Utang marang nilai buku Mainz Biomed|MYNZ - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Mainz Biomed|Likuiditas cepet mainzbiomed.com
- data bathi resik lan rasio valuasi:
MYNZ - Bathi perusahaan
Pambiji fundamental perusahaan:Mainz Biomed N.V.
Produk dadi Mainz Biomed

Analyzing financial leverage—calculated as the ratio of total liabilities to equity to assess a business's dependence on external borrowing—is critical for constructing a defensive portfolio. In the case of Mainz Biomed N.V. (MYNZ), this balance between debt and equity demonstrates the company's ability to fund the development of the innovative ColoAlert test without excessive credit pressure, thereby minimizing bankruptcy risks amid tight monetary policy.

Analisis pesaing Mainz Biomed N.V.

CAI (Caris Life Sciences) - Total Utang marang Modal|Rasio Total Utang marang Ekuitas Guardant Health Inc (GH)|Total Utang marang Modal VCYT|Total Utang marang Modal Celcuity Therapeutics (CELC)|Utang marang Ekuitas GRAIL, Inc. GRAL|MYGN: Rasio Utang marang Ekuitas|Castle Biosciences, Inc. - Total Utang marang Modal|Burning Rock Biotech Limited (BNR) - Rasio Total Utang marang Ekuitas|VNRX: Total Utang marang Modal|Utang marang Modal Biodesix Corporation (BDSX)|Utang marang Ekuitas Precipio, Inc.|CHEK: Rasio Kabeh Utang marang Dana Pribadi|Rasio Total Utang marang Ekuitas OCX (OncoCyte)